Literature DB >> 28805961

Reducing Branded Prescription Drug Prices: A Review of Policy Options.

G Caleb Alexander1,2,3, Jeromie Ballreich1,4, Mariana P Socal1,5, Taruja Karmarkar1,4, Antonio Trujillo5, Jeremy Greene3, Joshua Sharfstein1,6, Gerard Anderson1,4.   

Abstract

The high prices of specialty pharmaceuticals are causing some public programs to ration care and many private insurers, including Medicare drug plans, to place specialty drugs on high cost-sharing tiers. As a result, access to these drugs is often restricted, and only a small portion of the population with a disease may receive treatment. This concern has generated a wide range of proposed solutions. We conducted a literature review and identified 52 solutions in the peer-reviewed literature that we classified into five broad categories: revising the patent system, encouraging research to increase development of new drugs, altering pharmaceutical regulation, decreasing market demand, and developing innovative pricing strategies. We discuss the rationale for these five approaches and summarize the proposed solutions. We also discuss four empirical issues that are particularly important in any discussion of policy options.
© 2017 Pharmacotherapy Publications, Inc.

Keywords:  drug costs; drug pricing; out-of-pocket costs; pharmaceutical policy; prescription drugs

Mesh:

Substances:

Year:  2017        PMID: 28805961     DOI: 10.1002/phar.2013

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors:  Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal:  Int J Health Serv       Date:  2022-05-12       Impact factor: 1.851

Review 2.  Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science.

Authors:  Maria Angelica Borges Dos Santos; Leticia Lucia Dos Santos Dias; Cláudia Du Bocage Santos Pinto; Rondineli Mendes da Silva; Claudia Garcia Serpa Osorio-de-Castro
Journal:  J Pharm Policy Pract       Date:  2019-06-27

3.  Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE.

Authors:  Angela V Pérez; Antonio J Trujillo; Aurelio E Mejia; Johnny D Contreras; Joshua M Sharfstein
Journal:  Pharmacol Res Perspect       Date:  2019-12-10

4.  Trust and willingness towards COVID-19 vaccine uptake: a mixed-method study in Ghana, 2021.

Authors:  Joshua Amo-Adjei; Anastasiia Nurzhynska; Ruth Essuman; Anna-Leena Lohiniva
Journal:  Arch Public Health       Date:  2022-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.